Knight Therapeutics Inc traded at 7.65 this Friday April 17th, decreasing 0.02 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, Knight Therapeutics lost 23.99 percent. Over the last 12 months, its price rose by 32.35 percent. Looking ahead, we forecast Knight Therapeutics Inc to be priced at 7.49 by the end of this quarter and at 7.04 in one year, according to Trading Economics global macro models projections and analysts expectations.
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.